Werewolf Therapeutics Inc. (NASDAQ: HOWL) is -84.63% lower on its value in year-to-date trading and has touched a low of $1.62 and a high of $16.32 in the current 52-week trading range. The question becomes, what are the chances the stock will make a comeback and enjoy potential growth. Why not look at analysts view on what the future holds for the stock. The HOWL stock was last observed hovering at around $1.73 in the last trading session, with the day’s gains setting it 0.1% off its average median price target of $19.00 for the next 12 months. It is also 90.85% off the consensus price target high of $20.00 offered by 4 analysts, but current levels are 77.12% higher than the price target low of $8.00 for the same period.
Currently trading at $1.83, the stock is -23.74% and -50.69% below its SMA20 and SMA50 respectively. However, with a daily trading volume of 0.24 million and changing 5.78% at the moment leaves the stock -61.78% off its SMA200. HOWL registered -87.59% loss for a year compared to 6-month loss of -56.22%.
The stock witnessed a -46.65% gain in the last 1 month and extending the period to 3 months gives it a -68.82%, and is -2.14% down over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 13.37% over the week and 12.54% over the month.
Werewolf Therapeutics Inc. (HOWL) has around 48 employees, a market worth around $54.11M and $9.10M in sales. Distance from 52-week low is 12.62% and -88.79% from its 52-week high.
Werewolf Therapeutics Inc. (HOWL) Analyst Forecasts
Analyst recommendations provided by FactSet shows that the consensus forecast for Werewolf Therapeutics Inc. (HOWL) is a “Buy”. 4 analysts offering their recommendations for the stock have an average rating of 1.20, where 0 rate it as a Hold and 0 think it is a “Overweight”. 4 of the analysts rate the stock as a “Buy”. 0 analysts have rated the stock as a Sell or Underperform.
Werewolf Therapeutics Inc. is expected to release its quarterly report on 03/23/2023.The EPS is expected to shrink by -621.50% this year
Werewolf Therapeutics Inc. (HOWL) Top Institutional Holders
The shares outstanding are 29.76M, and float is at 25.07M with Short Float at 0.61%.
Werewolf Therapeutics Inc. (HOWL) Insider Activity
A total of 0 insider transactions have happened at Werewolf Therapeutics Inc. (HOWL) in the last six months, with sales accounting for 0 and purchases happening 0 times. The most recent transaction is an insider sale by Leonard Reid, the company’s Chief Operating Officer. SEC filings show that Leonard Reid sold 3,000 shares of the company’s common stock on Dec 15 at a price of $13.41 per share for a total of $40242.0. Following the sale, the insider now owns 0.12 million shares.
Werewolf Therapeutics Inc. (HOWL): Who are the competitors?
The company’s main competitors (and peers) include Rogers Corporation (ROG) that is -59.94% lower over the past 12 months. Bristol-Myers Squibb Company (BMY) is 37.75% up on the 1-year trading charts.